Pharmacological and cognitive-behavioral therapy treatments for depression are relatively well developed and play an important role in reducing the adverse impact of depression. With the advent of the selective serotonin reuptake inhibitors to treat depression, more medically ill patients can be treated without the complicating cardiovascular side effects of the previous drugs available. Ongoing research is investigating whether these treatments also reduce the associated risk of a second heart attack. Furthermore, preventive interventions based on cognitive-behavior theories of depression also merit attention as approaches for avoiding adverse outcomes associated with both disorders. These interventions may help promote adherence and behavior change that may increase the impact of available pharmacological and behavioral approaches to both diseases.
Exercise is another potential pathway to reducing both depression and heart disease.
Exercise is related to fewer depressive symptoms in observational studies and appears to be as efficacious as psychotherapy in patients with mild depression. Exercise, of course, is a major protective factor against heart disease as well. The NIMH and the National Heart, Lung and Blood Institute are invested in uncovering the complicated relationship between depression and heart disease. They support research on the basic mechanisms and processes linking co-morbid mental and medical disorders to identify potent, modifiable risk factors and protective processes amenable to medical and behavioral interventions that will reduce the adverse outcomes associated with both types of disorders. By clicking the 'Search' button, you agree to the terms and conditions under Disclaimer .